Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14193287 | 1.00 | FYN (0.48) | FYNDRD2DRD3FUCA1GRIN2B | |
| SCHEMBL8365487 | 0.94 | FYN (0.48) | FYNDRD2DRD3FUCA1GRIN2B | |
| SCHEMBL4825520 | 0.94 | FYN (0.48) | FYNDRD2DRD3FUCA1GRIN2B | |
| SCHEMBL1363371 | 0.76 | DRD2 (0.61) | DRD2DRD3CYP19A1DRD4 | |
| SCHEMBL11960199 | 0.75 | DRD2 (0.71) | FYNDRD2DRD3GRIN2BDRD4 | |
| SCHEMBL10043007 | 0.75 | DRD2 (0.71) | FYNDRD2DRD3GRIN2BDRD4 | |
| SCHEMBL10043005 | 0.75 | DRD2 (0.71) | FYNDRD2DRD3GRIN2BDRD4 | |
| SCHEMBL4824109 | 0.73 | KDM4E (0.45) | DRD2 | |
| SCHEMBL14193298 | 0.73 | KDM4E (0.45) | DRD2 | |
| SCHEMBL7564804 | 0.73 | DRD2 (0.61) | FYNDRD2DRD3GRIN2BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365061-B2 | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2006055463-A2 | 2-AMINO-3-FUNCTIONALIZED TETRALIN DERIVATIVES AND RELATED GLYCOGEN PHOSPHORYLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111413-A1 | Antidiabetic agents, anticancer, non-cardiac ischemia, infection, hypertension, obesity and dislipidemia; 3-(5-chloroindole-2-carbonylamino)-2-hydroxy-1,2,3,4-tetrahydronaphthalene | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111413-A1 | Antidiabetic agents, anticancer, non-cardiac ischemia, infection, hypertension, obesity and dislipidemia; 3-(5-chloroindole-2-carbonylamino)-2-hydroxy-1,2,3,4-tetrahydronaphthalene | PYGM, PON1, GYS1 | FYN 3310/4885DRD2 4418/4885DRD3 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.